APA Citation

National Cancer Institute (NCI). (2019). A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects. Bethesda (Maryland): ClinicalTrials.gov.

Chicago Style Citation

National Cancer Institute (NCI). A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects. Bethesda (Maryland): ClinicalTrials.gov, 2019.

MLA Citation

National Cancer Institute (NCI). A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects. Bethesda (Maryland): ClinicalTrials.gov, 2019.

Warning: These citations may not always be 100% accurate.